| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
62,030,000 |
| Market
Cap: |
903.16(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.48 - $21.47 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile MacroGenics is a biopharmaceutical company. Co.'s main pipeline program is MGC018, an antibody-drug conjugate that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Co. is also developing enoblituzumab, an Fc-optimized monoclonal antibody that targets B7-H3 and molecules that target programmed cell death protein 1, a protein that is important in the regulation of the immune system's response to cancer. In addition, Co. is developing MGD024, a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
350,000 |
2,394,399 |
| Total Buy Value |
$0 |
$0 |
$1,722,425 |
$11,462,434 |
| Total People Bought |
0 |
0 |
1 |
2 |
| Total Buy Transactions |
0 |
0 |
2 |
11 |
| Total Shares Sold |
261,204 |
293,400 |
293,400 |
298,772 |
| Total Sell Value |
$4,645,136 |
$4,995,238 |
$4,995,238 |
$5,027,631 |
| Total People Sold |
5 |
5 |
5 |
5 |
| Total Sell Transactions |
9 |
11 |
11 |
12 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2019-01-28 |
4 |
OE |
$0.94 |
$5,640 |
D/D |
6,000 |
28,309 |
|
- |
|
| Karrels James |
SVP, CFO and Secretary |
• – – |
2019-01-24 |
4 |
OE |
$0.94 |
$6,886 |
D/D |
7,326 |
135,487 |
|
- |
|
| Karrels James |
SVP, CFO and Secretary |
• – – |
2019-01-08 |
4 |
OE |
$0.94 |
$4,995 |
D/D |
5,314 |
128,161 |
|
- |
|
| Koenig Scott |
President and CEO |
• • – |
2019-01-03 |
4 |
OE |
$0.94 |
$37,503 |
D/D |
39,897 |
213,060 |
|
- |
|
| Karrels James |
SVP, CFO and Secretary |
• – – |
2018-12-18 |
4 |
OE |
$0.94 |
$4,700 |
D/D |
5,000 |
122,847 |
|
- |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2018-12-12 |
4 |
OE |
$0.94 |
$4,700 |
D/D |
5,000 |
22,309 |
|
- |
|
| Karrels James |
SVP, CFO and Secretary |
• – – |
2018-11-27 |
4 |
OE |
$0.94 |
$2,820 |
D/D |
3,000 |
117,847 |
|
- |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2018-11-13 |
4 |
OE |
$0.94 |
$3,760 |
D/D |
4,000 |
16,100 |
|
- |
|
| Koenig Scott |
President and CEO |
• • – |
2018-11-13 |
4 |
OE |
$0.94 |
$37,600 |
D/D |
40,000 |
173,163 |
|
- |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2018-10-22 |
4 |
OE |
$0.94 |
$2,820 |
D/D |
3,000 |
12,100 |
|
- |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2018-03-12 |
4 |
AS |
$31.08 |
$31,080 |
D/D |
(1,000) |
9,100 |
|
- |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2018-03-12 |
4 |
OE |
$0.94 |
$940 |
D/D |
1,000 |
10,100 |
|
- |
|
| Karrels James |
SVP, CFO and Secretary |
• – – |
2018-03-05 |
4 |
AS |
$31.00 |
$155,000 |
D/D |
(5,000) |
114,847 |
|
- |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2018-03-02 |
4 |
AS |
$30.00 |
$120,000 |
D/D |
(4,000) |
9,100 |
|
- |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2018-03-02 |
4 |
OE |
$0.94 |
$3,760 |
D/D |
4,000 |
13,100 |
|
- |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2018-02-28 |
4 |
AS |
$25.01 |
$25,005 |
D/D |
(1,000) |
9,100 |
|
- |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2018-02-28 |
4 |
OE |
$0.94 |
$940 |
D/D |
1,000 |
10,100 |
|
- |
|
| Cilinski Lynn |
VP, Controller and Treasurer |
• – – |
2018-02-28 |
4 |
AS |
$25.01 |
$599,436 |
D/D |
(23,967) |
1,923 |
|
- |
|
| Cilinski Lynn |
VP, Controller and Treasurer |
• – – |
2018-02-28 |
4 |
OE |
$0.94 |
$27,083 |
D/D |
23,967 |
25,890 |
|
- |
|
| Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
• – – |
2018-02-26 |
4 |
D |
$23.46 |
$259,702 |
D/D |
(11,070) |
18,930 |
|
- |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2018-01-24 |
4 |
AS |
$22.50 |
$67,500 |
D/D |
(3,000) |
9,100 |
|
- |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2018-01-24 |
4 |
OE |
$0.94 |
$2,820 |
D/D |
3,000 |
12,100 |
|
- |
|
| Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
• – – |
2018-01-17 |
4 |
AS |
$20.00 |
$50,480 |
D/D |
(2,524) |
30,000 |
|
- |
|
| Wigginton Jon Marc |
Sr VP, Clinical Dev. & CMO |
• – – |
2018-01-17 |
4 |
OE |
$4.70 |
$11,863 |
D/D |
2,524 |
32,524 |
|
- |
|
| Risser Eric Blasius |
Sr VP & Chief Business Officer |
• – – |
2018-01-17 |
4 |
OE |
$0.94 |
$1,880 |
D/D |
2,000 |
9,100 |
|
- |
|
286 Records found
|
|
Page 6 of 12 |
|
|
0.19 (1.32%) 
